Search company, investor...
Biosplice Therapeutics company logo

Biosplice Therapeutics

biosplice.com

Total Raised

$561.5M

Investors Count

10

Deal Terms

1

Funding, Valuation & Revenue

6 Fundings

Biosplice Therapeutics's latest funding round was a Series B for $120M on April 15, 2021.

Biosplice Therapeutics's valuation in August 2018 was $12,000M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

4/15/2021

Series B

$120M

0

FY undefined

16

4/27/2020

Loan

$99M

0

FY undefined

0

8/6/2018

Series A

$99M

$12,000M

0

FY undefined

10

1/2/2012

Unattributed VC

0

FY undefined

10

10/14/2008

Incubator/Accelerator

0

FY undefined

10

Date

4/15/2021

4/27/2020

8/6/2018

1/2/2012

10/14/2008

Round

Series B

Loan

Series A

Unattributed VC

Incubator/Accelerator

Amount

$120M

$99M

$99M

Investors

Valuation

$12,000M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

16

0

10

10

10

This profile has not been claimed.

You're more than your latest funding, tell our customers your company's story.

Biosplice Therapeutics Deal Terms

1 Deal Term

Biosplice Therapeutics's deal structure is available for 1 funding round, including their Series A from August 06, 2018.

Round

Series A

Funding Date

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$99M

$99M

$99M

$99M

$99M

$99M

Biosplice Therapeutics Investors

10 Investors

Biosplice Therapeutics has 10 investors. SymBiosis invested in Biosplice Therapeutics's Series B funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

4/15/2021

4/15/2021

1
Series B

Corporation

DC

4/15/2021

4/15/2021

1
Series B

Asset/Investment Management

Connecticut

4/15/2021

4/15/2021

1
Series B

Venture Capital

Virginia

00/00/0000

00/00/0000

Eventide Asset Management

Subscribe to see more

Mutual Fund

Nebraska

00/00/0000

00/00/0000

aMoon Fund

Subscribe to see more

Venture Capital

Israel

First funding

4/15/2021

4/15/2021

4/15/2021

00/00/0000

00/00/0000

Last Funding

4/15/2021

4/15/2021

4/15/2021

00/00/0000

00/00/0000

Investor

Eventide Asset Management

aMoon Fund

Rounds

1
Series B
1
Series B
1
Series B

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Asset/Investment Management

Venture Capital

Mutual Fund

Venture Capital

Location

DC

Connecticut

Virginia

Nebraska

Israel

Compare Biosplice Therapeutics to Competitors

L
Lubris BioPharma

Lubris BioPharma is a development-stage life science company producing and commercializing a recombinant version of the human protein, lubricin. Lubricin is expressed in numerous parts of the human body and plays an important role in protecting surfaces from damage and wear. Opinion leaders and clinicians worldwide are focusing their research efforts on using lubricin to improve the lives of millions of people with a host of unmet medical needs including dry eye, osteoarthritis, surgical adhesions, xerostomia, and pericarditis.

Oyster Point Pharma Logo
Oyster Point Pharma

Oyster Point Pharma (NASDAQ: OYST) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of therapies to treat diseases with high unmet needs. The company's initial focus is to develop therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. The company was founded in 2015 and is based in Princeton, New Jersey.

Aldeyra Therapeutics Logo
Aldeyra Therapeutics

Aldeyra Therapeutics, formerly Neuron Systems, is a biotechnology company focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The company discovered and is developing NS2, a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of Sjogren-Larsson Syndrome (SLS), a rare disease caused by mutations in an enzyme that metabolizes fatty aldehydes, and acute anterior uveitis, an inflammatory eye disease.

Bioventus Logo
Bioventus

Bioventus (NASDAQ: BVS) is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.